MLN0128

Phase 2Small molecule

Takeda

MLN0128 is one of 234 small molecule programs targeting Triple-Negative Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

233

Competitors

Pipeline

Status by Indication[3][1]

Indication

Triple-Negative Breast CancerActive, not recruiting

Prostate CancerActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

Thyroid CancerActive, not recruiting

Merkel Cell CarcinomaActive, not recruiting

Waldenstrom MacroglobulinemiaActive, not recruiting

Triple-Negative Breast CancerPhase 1

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Hepatocellular CarcinomaPhase 1/Phase 2

Active, not recruiting

Renal Cell CarcinomaPhase 2

Active, not recruiting

Thyroid CancerPhase 1/Phase 2

Active, not recruiting

Merkel Cell CarcinomaPhase 1/Phase 2

Active, not recruiting

Waldenstrom MacroglobulinemiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

MLN0128

Takeda

Phase 2

1 2

Novantrone

Pfizer

Preclinical

5 3

Mekinist

Novartis

Preclinical

3 4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 5

Duragesic

CCephalon

Preclinical

1 6

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 7

Prednisone/prednisolone

Roche

Preclinical

3 8

Triptorelin Pamoate

Ipsen

Preclinical

2 9

Osmitrol

BB. Braun Medical Inc.

Preclinical

—10

Ifex

BBaxter Healthcare Corporation

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma1 trial

MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma

Terminated·KKathy Miller·Phase 1/2·NCT02575339·11 enrolled

Waldenstrom macroglobulinemia1 trial

Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia

Completed· Takeda logo

Takeda·Phase 1·NCT01118689·39 enrolled

Thyroid Cancer1 trial

A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer

Completed·—·Phase 1/2·NCT02244463·46 enrolled

Prostate Cancer1 trial

Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT02091531·9 enrolled

Advanced Malignancies1 trial

Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies

Completed· Takeda logo

Takeda·Phase 1·NCT01058707·198 enrolled

5 more indications

Advanced Solid Malignancies1 trial

Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies

Completed· Takeda logo

Takeda·Phase 1·NCT01351350·68 enrolled

Hematologic Malignancies1 trial

A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies

Completed· Takeda logo

Takeda·Phase 1·NCT02327169·81 enrolled

Renal Cell Carcinoma1 trial

MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma

Completed· Takeda logo

Takeda·Phase 2·NCT02724020·96 enrolled

Merkel Cell Carcinoma1 trial

MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma

Completed·—·Phase 1/2·NCT02514824·9 enrolled

Triple-Negative Breast Cancer1 trial

Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer

Completed·UUniversity of Colorado, Denver·Phase 1·NCT02719691·47 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for MLN0128. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MLN0128 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MLN0128. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Takeda

MLN0128

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hepatocellular Carcinoma1 trial

Waldenstrom macroglobulinemia1 trial

Thyroid Cancer1 trial

Prostate Cancer1 trial

Advanced Malignancies1 trial

Advanced Solid Malignancies1 trial

Hematologic Malignancies1 trial

Renal Cell Carcinoma1 trial

Merkel Cell Carcinoma1 trial

Triple-Negative Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News